Previous close | 0.9000 |
Open | 1.0500 |
Bid | 0.6500 |
Ask | 1.2000 |
Strike | 25.00 |
Expiry date | 2024-06-21 |
Day's range | 0.9000 - 1.0500 |
Contract range | N/A |
Volume | |
Open interest | 212 |
Q4 2024 Roivant Sciences Ltd Earnings Call
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.